SCHEMBL4024326

SCHEMBL4024326

O=C(O)CCCNS(=O)(=O)c1ccc(CN(Cc2cccc(C(F)(F)F)c2)C(=O)C(=O)O)s1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TSHR P16473 1/20 0.44
SERPINE1 P05121 2/20 0.40
S1PR4 O95977 2/20 0.40
S1PR5 Q9H228 2/20 0.40
TBXAS1 P24557 1/20 0.39
FFAR1 O14842 2/20 0.38
FFAR4 Q5NUL3 2/20 0.38
PTGES O14684 1/20 0.38
PTGER1 P34995 1/20 0.37
PTGFR P43088 1/20 0.37
PPARG P37231 1/20 0.37
LMNA P02545 2/20 0.36
RAB9A P51151 1/20 0.36
NR3C1 P04150 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4016045 0.90 SMN1; SMN2 (0.42) SMN1; SMN2TSHRSERPINE1PTGESLMNA
SCHEMBL1854854 0.90 SMN1; SMN2 (0.42) SMN1; SMN2TSHRSERPINE1PTGESLMNA
SCHEMBL4019783 0.89 MAPK1 (0.41) MAPK1SMN1; SMN2TSHRS1PR4S1PR5
SCHEMBL1852522 0.88 TRPM8 (0.43) SMN1; SMN2SERPINE1PTGESPPARGLMNA
SCHEMBL1852016 0.86 SERPINE1 (0.42) SMN1; SMN2TSHRSERPINE1PTGESPPARG
SCHEMBL1855180 0.84 MAPK14 (0.43) SERPINE1FFAR1FFAR4PTGESNR3C1
SCHEMBL4022922 0.82 EPHX1 (0.39) SMN1; SMN2TSHRSERPINE1PTGESPPARG
SCHEMBL4017082 0.81 SERPINE1 (0.40) SMN1; SMN2SERPINE1PTGESPPARGLMNA
SCHEMBL1852104 0.77 KMT2A (0.50) MAPK1SMN1; SMN2TSHRLMNAALDH1A1
SCHEMBL1853214 0.76 TSHR (0.43) MAPK1SMN1; SMN2TSHRLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 US claimed
EP-1986637-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS Laboratoires Serono SA (CH) 2008-11-05 EP claimed
WO-2007093557-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS LABORATOIRES SERONO S.A. (CH) 2007-08-23 WO claimed
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 US disclosed
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 US disclosed
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 US disclosed
EP-1986637-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS Laboratoires Serono SA (CH) 2008-11-05 EP disclosed
WO-2007093557-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS LABORATOIRES SERONO S.A. (CH) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections STS, TST, SULT1A1 MAPK1 2747/4885SMN1; SMN2 2147/4885TSHR 1632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.